This reports provides a data-driven overview of the current and future competitive landscape in Focal Segmental Glomerulosclerosis therapeutics.
- In 2024, more than 36,000 diagnosed incident cases of FSGS are anticipated in the 16 countries covered in the analyst’s epidemiology forecast for FSGS.
- There's a significant gap in the market for disease modifying and effective treatment as the current market is catered by only the off-label usage of drugs for symptomatic treatment.
- There are 22 molecules in the pipeline for FSGS. The Phase III pipeline consists of three drugs, followed by five drugs in Phase II.
- Over the past 10 years, the US has hosted the highest number of trial sites for FSGS, at more than 500 trial sites.
- In past decade, acquisitions were the predominant type of deal in North America. In Europe, licensing agreements were most frequent deal type.
Scope
The Focal Segmental Glomerulosclerosis: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.Components of the report include :
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the Focal Segmental Glomerulosclerosis market.
- Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Focal Segmental Glomerulosclerosis market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
1 Table of Contents2 Key Findings10 Future Market Catalysts
1 Preface
3 Disease Landscape
4 Marketed Drugs Assessment
5 Pricing and Reimbursement Assessment
6 Pipeline Drugs Assessment
7 Clinical Trials Assessment
8 Deals Landscape
9 Commercial Assessment
11 Appendix